Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biomarin Pharmaceutical Inc
Cash from Operating Activities
Biomarin Pharmaceutical Inc
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
Cash from Operating Activities
$280.1m
|
CAGR 3-Years
9%
|
CAGR 5-Years
105%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$8B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$8.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
$3.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$4.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
See Also
What is Biomarin Pharmaceutical Inc's Cash from Operating Activities?
Cash from Operating Activities
280.1m
USD
Based on the financial report for Mar 31, 2024, Biomarin Pharmaceutical Inc's Cash from Operating Activities amounts to 280.1m USD.
What is Biomarin Pharmaceutical Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
105%
Over the last year, the Cash from Operating Activities growth was 90%. The average annual Cash from Operating Activities growth rates for Biomarin Pharmaceutical Inc have been 9% over the past three years , 105% over the past five years .